A chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatment

dc.creatorKumar, Manish
dc.creatorTaki, Kaling
dc.creatorGahlot, Rohit
dc.creatorSharma, Ayushi
dc.creatorDhangar, Kiran
dc.date.accessioned2020-07-30T16:57:47Z
dc.date.available2020-07-30T16:57:47Z
dc.date.created2020
dc.description.abstractIn order to benefit the public, community workers and scientific community, we hereby present a chronicle of SARSCoV-2 that leads to the unseen precedent of social distancing and lockdown owing to coronavirus disease (COVID19). Information on this life-threatening pandemic of COVID-19 is sparse and discrete; and the urgency is such that the dissemination of information is increasing with numerous daily publications on the topic. Therefore, we developed a comprehensive review on various aspects of SARS-CoV-2 and COVID-19. We scientifically compiled published research, news, and reports from various sources to comprehend and summarize the information and findings on Coronaviruses. The review explicitly covers the aspects like genome and pedigree of SARS-CoV-2; epidemiology, prognosis, pathogenesis, symptoms and diagnosis of COVID-19 in order to catalog the right information on transmission route, and influence of environmental factors on virus transmissions, for the robust understanding of right strategical steps for proper COVID-19 management. We have explicitly highlighted several useful information and facts like: i) No established relationship between progression of SARS-CoV-2 with temperature, humidity and/or both, ii) The underlying mechanism of SARS-CoV-2 is not fully understood, iii) Respiratory droplet size determines drop and airborne-based transmission, iv) Prognosis of COVID-19 can be done by its effects on various body organs, v) Infection can be stopped by restricting the binding of S protein and AE2, vi) Hydroxychloroquine is believed to be better than chloroquine for COVID-19, vii) Ivermectin with Vero-hSLAM cells is able to reduce infection by ~5000 time within 2 days, and viii) Nafamostat mesylate can inhibit SARS-CoV-2 S protein-initiated membrane fusion. We have also suggested future research perspectives, challenges and scope.spa
dc.format.extent13 páginasspa
dc.format.mimetypeimage/jepgspa
dc.identifier.doihttps://doi.org/10.1016/j.scitotenv.2020.139278spa
dc.identifier.issn0048-9697spa
dc.identifier.otherhttps://doi.org/10.1016/j.scitotenv.2020.139278spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/11426
dc.publisherThe Science of the total environmenteng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectSARS-CoV-2spa
dc.subjectSARS-CoVspa
dc.subjectMERS-CoVspa
dc.subjectCOVID-19spa
dc.subjectTransmissionspa
dc.subjectPathogenesisspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleA chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatmentspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 2 de 2
Cargando...
Miniatura
Nombre:
Captura.PNG
Tamaño:
178.3 KB
Formato:
Portable Network Graphics
Descripción:
Ver portada
Cargando...
Miniatura
Nombre:
A-chronicle-of-SARS-CoV-2--Part-I---Epidemiology--dia_2020_Science-of-The-To.pdf
Tamaño:
2.77 MB
Formato:
Adobe Portable Document Format
Descripción:
Artículo reservado

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción: